journal
https://read.qxmd.com/read/37236186/distortion-of-journal-impact-factors-in-the-era-of-paper-mills
#1
EDITORIAL
Courtney Bricker-Anthony, Roland W Herzog
No abstract text is available yet for this article.
May 25, 2023: Molecular Therapy
https://read.qxmd.com/read/37236185/can-msh3-lowering-stop-htt-repeat-expansion-in-its-cag-tract
#2
JOURNAL ARTICLE
Ross Ferguson, Sarah J Tabrizi
No abstract text is available yet for this article.
May 25, 2023: Molecular Therapy
https://read.qxmd.com/read/37244253/rescue-of-auditory-function-by-a-single-administration-of-aav-tmprss3-gene-therapy-in-aged-mice-of-human-recessive-deafness-dfnb8
#3
JOURNAL ARTICLE
Wan Du, Volkan Ergin, Corena Loeb, Mingqian Huang, Stewart Silver, Ariel Miura Armstrong, Zaohua Huang, Channabasavaiah B Gurumurthy, Hinrich Staecker, Xuezhong Liu, Zheng-Yi Chen
Patients with mutations in the TMPRSS3 gene suffer from recessive deafness DFNB8/DFNB10. For these patients, cochlear implantation is the only treatment option. Poor cochlear implantation outcomes are seen in some patients. To develop biological treatment for TMPRSS3 patients, we generated a knockin mouse model with a frequent human DFNB8 TMPRSS3 mutation. The Tmprss3A306T/A306T homozygous mice display delayed onset progressive hearing loss similar to human DFNB8 patients. Using AAV2 as a vector to carry a human TMPRSS3 gene, AAV2-hTMPRSS3 injection in the adult knockin mouse inner ear results in TMPRSS3 expression in the hair cells and the spiral ganglion neurons...
May 22, 2023: Molecular Therapy
https://read.qxmd.com/read/37211762/polyphyllin-d-punctures-hypertrophic-lysosomes-to-reverse-drug-resistance-of-hepatocellular-carcinoma-by-targeting-acid-sphingomyelinase
#4
JOURNAL ARTICLE
Yang Wang, Yan-Yan Chen, Gui-Bin Gao, Yang-Han Zheng, Nan-Nan Yu, Lan Ouyang, Xuejuan Gao, Nan Li, Shi-Yuan Wen, Shangjia Huang, Qian Zhao, Langxia Liu, Mingrong Cao, Shuixing Zhang, Jing Zhang, Qing-Yu He
Hypertrophic lysosomes are critical for tumor progression and drug resistance; however, effective and specific lysosome targeting compounds for cancer therapy are lacking. Here we conducted a lysosomotropic pharmacophore-based in silico screen in a natural product library (2212 compounds), and identified Polyphyllin D (PD) as a novel lysosome-targeted compound. PD treatment was found to cause lysosomal damage, as evidenced by the blockade of autophagic flux, loss of lysophagy, and the release of lysosomal contents, thus exhibiting anticancer effects on hepatocellular carcinoma (HCC) cell both in vitro and in vivo...
May 21, 2023: Molecular Therapy
https://read.qxmd.com/read/37201525/always-a-bridesmaid-never-a%C3%A2-bride-committing-to-flu-neuraminidase-as-a-vaccine-target
#5
JOURNAL ARTICLE
Cosette Schneider, Lynda Coughlan
No abstract text is available yet for this article.
May 17, 2023: Molecular Therapy
https://read.qxmd.com/read/37198883/tracking-human-neurologic-disease-status-in-mouse-brain-plasma-using-reporter-tagged-ev-associated-biomarkers
#6
JOURNAL ARTICLE
Katia E Maalouf, Christine A Vaine, Dawn M Frederick, Akiko Yoshinaga, Wataru Obuchi, Shadi Mahjoum, Lisa Nieland, Jamal Al Ali, D Cristopher Bragg, Xandra O Breakefield, Koen Breyne
X-linked dystonia-parkinsonism (XDP) is a neurodegenerative disease caused by a retrotransposon insertion in intron 32 of the TAF1 gene. This insertion causes mis-splicing of intron 32 (TAF1-32i) and reduced TAF1 levels. TAF1-32i transcript is unique to XDP patient cells and can be detected in their extracellular vesicles (EVs). We engrafted patient and control iPSC-derived neural progenitor cells (hNPCs) into the striatum of mice. To track TAF1-32i transcript spread by EVs, we transduced the brain-implanted hNPCs with a lentiviral construct called ENoMi which consists of a re-engineered tetraspanin scaffold tagged with bioluminescent and fluorescent reporter proteins under an EF-1α promoter...
May 16, 2023: Molecular Therapy
https://read.qxmd.com/read/37194237/extracellular-communication-between-brain-cells-through-functional-transfer-of-cre-mrna-mediated-by-extracellular-vesicles
#7
JOURNAL ARTICLE
David Rufino-Ramos, Kevin Leandro, Pedro R L Perdigão, Killian O'Brien, Maria Manuel Pinto, Magda M Santana, Thomas S van Solinge, Shadi Mahjoum, Xandra O Breakefield, Koen Breyne, Luís Pereira de Almeida
In the central nervous system (CNS), the crosstalk between neural cells is mediated by extracellular mechanisms, including brain-derived extracellular vesicles (bdEVs). To study endogenous communication across the brain and periphery, we explored Cre-mediated DNA recombination to permanently record the functional uptake of bdEVs cargo overtime. To elucidate functional cargo transfer within the brain at physiological levels, we promoted the continuous secretion of physiological levels of neural bdEVs containing Cre mRNA from a localized region in the brain by in situ lentiviral transduction of the striatum of Flox-tdTomato Ai9 mice reporter of Cre activity...
May 15, 2023: Molecular Therapy
https://read.qxmd.com/read/37194236/chimeric-tim-4-receptor-modified-t-cells-targeting-phosphatidylserine-mediates-both-cytotoxic-anti-tumor-responses-and-phagocytic-uptake-of-tumor-associated-antigen-for-t-cell-cross-presentation
#8
JOURNAL ARTICLE
Brandon Cieniewicz, Ankit Bhatta, Damoun Torabi, Priya Baichoo, Mike Saxton, Alexander Arballo, Linh Nguyen, Sunil Thomas, Harini Kethar, Phanidhar Kukutla, Omolola Shoaga, Bi Yu, Zhuo Yang, Maria Fate, Edson Oliveira, Hongxiu Ning, Lawrence Corey, Daniel Corey
To leverage complementary mechanisms for cancer cell removal, we developed a novel cell engineering and therapeutic strategy co-opting phagocytic clearance and antigen presentation activity into T cells. We engineered a chimeric engulfment receptor, (CER)-1236, that combines the extracellular domain of TIM-4, a phagocytic receptor recognizing the 'eat me' signal phosphatidylserine, with intracellular signaling domains (TLR2/TIR, CD28, and CD3ζ) to enhance both TIM-4-mediated phagocytosis and T-cell cytotoxic function...
May 15, 2023: Molecular Therapy
https://read.qxmd.com/read/37179456/targeted-therapy-for-rare-lung-cancers-status-challenges-and-prospects
#9
REVIEW
Chunsen Wang, Xiang Yuan, Jianxin Xue
Lung cancer causes the most cancer-related deaths worldwide. In recent years, molecular and immunohistochemical techniques have rapidly developed, further inaugurating an era of personalized medicine for lung cancer. The rare subset of lung cancers accounts for approximately ten percent, each displaying distinct clinical characteristics. Treatments for rare lung cancers are mainly based on evidence from common counterparts, which may lead to unsolid clinical benefits considering intertumoral heterogeneity. The increasing knowledge of molecular profiling of rare lung cancers has made targeting genetic alterations and immune checkpoints a powerful strategy...
May 13, 2023: Molecular Therapy
https://read.qxmd.com/read/37178690/emerging-roles-of-the-crosstalk-between-non-coding-rnas-and-m-6-a-modification-in-cancers
#10
JOURNAL ARTICLE
Ludi Yang, Xianqun Fan, Peiwei Chai, Renbing Jia
No abstract text is available yet for this article.
May 12, 2023: Molecular Therapy
https://read.qxmd.com/read/37177784/di-valent-sirna-mediated-silencing-of-msh3-blocks-somatic-repeat-expansion-in-mouse-models-of-huntington-s-disease
#11
JOURNAL ARTICLE
Daniel O'Reilly, Jillian Belgrad, Chantal Ferguson, Ashley Summers, Ellen Sapp, Cassandra McHugh, Ella Mathews, Adel Boudi, Julianna Buchwald, Socheata Ly, Dimas Moreno, Raymond Furgal, Eric Luu, Zachary Kennedy, Vignesh Hariharan, Kathryn Monopoli, X William Yang, Jeffery Carroll, Marian DiFiglia, Neil Aronin, Anastasia Khvorova
Huntington's Disease (HD) is a severe neurodegenerative disorder caused by expansion of the CAG trinucleotide repeat tract in the huntingtin gene. Inheritance of expanded CAG repeats is needed for HD manifestation, but further somatic expansion of the repeat tract in non-dividing cells, particularly striatal neurons, hastens disease onset. Called somatic repeat expansion, this process is mediated by the mismatch repair (MMR) pathway. Among MMR components identified as modifiers of HD onset, MutS Homolog 3 (MSH3) has emerged as a potentially safe and effective target for therapeutic intervention...
May 11, 2023: Molecular Therapy
https://read.qxmd.com/read/37172590/retraction-notice-to-risk-associated-long-noncoding-rna-foxd3-as1-inhibits-neuroblastoma-progression-by-repressing-parp1-mediated-activation-of-ctcf
#12
Xiang Zhao, Dan Li, Dandan Huang, Huajie Song, Hong Mei, Erhu Fang, Xiaojing Wang, Feng Yang, Liduan Zheng, Kai Huang, Qiangsong Tong
No abstract text is available yet for this article.
May 11, 2023: Molecular Therapy
https://read.qxmd.com/read/37172589/beyond-the-unfolded-protein-response-disclosing-the-role-of-xbp1s-in-alzheimer-s-disease
#13
JOURNAL ARTICLE
Elena Marcello
No abstract text is available yet for this article.
May 11, 2023: Molecular Therapy
https://read.qxmd.com/read/37165619/plumbing-mysterious-rnas-in-dark-genome-for-the-conquest-of-human-diseases
#14
REVIEW
Lisa A Huang, Chunru Lin, Liuqing Yang
Next-generation sequencing has revealed that less than 2% of transcribed genes are translated into proteins, with a large portion transcribed into noncoding RNAs (ncRNAs). Among these, long non-coding RNA (lncRNA) represents the largest group and is pervasively transcribed throughout the genome. Dysfunctions in lncRNAs have been found in various diseases, highlighting their potential as therapeutic, diagnostic, and prognostic targets. However, challenges such as unknown molecular mechanisms and nonspecific immune responses, and issues of drug specificity and delivery present obstacles in translating lncRNA into clinical applications...
May 10, 2023: Molecular Therapy
https://read.qxmd.com/read/37165618/enhanced-adipose-derived-stem-cells-with-igf1-modified-mrna-promote-wound-healing-following-corneal-injury
#15
JOURNAL ARTICLE
Fei Yu, Danni Gong, Dan Yan, Huijing Wang, Nevin Witman, Yang Lu, Wei Fu, Yao Fu
The cornea serves as an important barrier structure to the eyeball and is vulnerable to injuries, which may lead to scarring and blindness if not treated promptly. In order to explore an effective treatment that could achieve multi-dimensional repair of the injured cornea, the study herein innovatively combined modified mRNA (modRNA) technologies with adipose derived mesenchymal stem cells (ADSCs) therapy, and applied IGF-1 modRNA (modIGF1) engineered ADSCs (ADSCmodIGF1 ) to alkali-burned corneas in mice. The therapeutic results showed that ADSCmodIGF1 treatment could achieve the most extensive recovery of corneal morphology and function when compared not only to simple ADSCs, but also IGF1 protein eyedrops, which was reflected by the healing of corneal epithelium and limbus, the inhibition of corneal stromal fibrosis, angiogenesis and lymphangiogenesis, and also the repair of corneal nerves...
May 10, 2023: Molecular Therapy
https://read.qxmd.com/read/37147804/targeting-long-non-coding-rna-nudt6-enhances-smooth-muscle-cell-survival-and-limits-vascular-disease-progression
#16
JOURNAL ARTICLE
Hanna Winter, Greg Winski, Albert Busch, Ekaterina Chernogubova, Francesca Fasolo, Zhiyuan Wu, Alexandra Bäcklund, Bohdan B Khomtchouk, Derek J Van Booven, Nadja Sachs, Hans-Henning Eckstein, Ilka Wittig, Reinier A Boon, Hong Jin, Lars Maegdefessel
Long non-coding RNAs (lncRNAs) orchestrate various biological processes and regulate the development of cardiovascular diseases. Their potential therapeutic benefit to tackle disease progression has recently been extensively explored. Our study investigates the role of lncRNA Nudix Hydrolase 6 (NUDT6) and its antisense target Fibroblast Growth Factor 2 (FGF2) in two vascular pathologies: abdominal aortic aneurysms (AAA) and carotid artery disease. Using tissue samples from both diseases, we detected a substantial increase of NUDT6, whereas FGF2 was downregulated...
May 5, 2023: Molecular Therapy
https://read.qxmd.com/read/37147803/a-chemically-inducible-il-2-receptor-signaling-complex-allows-for-effective-in-vitro-and-in-vivo-selection-of-engineered-cd4-t-cells
#17
JOURNAL ARTICLE
Peter J Cook, Su Jung Yang, Gene I Uenishi, Annaiz Grimm, Samuel E West, Li-Jie Wang, Chester Jacobs, Andrea Repele, Travis Drow, Ahmad Boukhris, Noelle P Dahl, Karen Sommer, Andrew M Scharenberg, David J Rawlings
Engineered T cells represent an emerging therapeutic modality. However, complex engineering strategies can present a challenge for enriching and expanding therapeutic cells at clinical scale. Additionally, lack of in vivo cytokine support can lead to poor engraftment of transferred T cells, including regulatory T cells (Treg ). Here, we establish cell-intrinsic selection system that leverages the dependency of primary T cells on IL-2 signaling. FRB-IL2RB and FKBP-IL2RG fusion proteins were identified permitting selective expansion of primary CD4+ T cells in rapamycin supplemented media...
May 4, 2023: Molecular Therapy
https://read.qxmd.com/read/37143325/mir-22-gene-therapy-treats-hcc-by-promoting-anti-tumor-immunity-and-enhancing-metabolism
#18
JOURNAL ARTICLE
Ying Hu, Tahereh Setayesh, Farzam Vaziri, Xuesong Wu, Samuel T Hwang, Xin Chen, Yu-Jui Yvonne Wan
MicroRNA-22 (miR-22) can be induced by beneficial metabolites that have metabolic and immune effects, including retinoic acids, bile acids, vitamin D3 , and short-chain fatty acids. The tumor suppressor effects of miR-22 have been suggested, but whether miR-22 treats orthotopic hepatocellular carcinoma (HCC) is not established. The role of miR-22 in regulating tumor immunity is poorly understood. Our data showed that miR-22 delivered by adeno-associated virus serotype 8 (AAV8) effectively treated HCC. Compared with FDA-approved Lenvatinib, miR-22 produced better survival outcomes without noticeable toxicity...
May 4, 2023: Molecular Therapy
https://read.qxmd.com/read/37143324/inhibition-of-c5ar1-impairs-osteoclast-mobilization-and-prevents-bone-loss
#19
JOURNAL ARTICLE
Carolina Pimenta-Lopes, Cristina Sánchez-de-Diego, Alexandre Deber, Andrea Egea-Cortés, José Antonio Valer, Albert Alcalá, Andrés Méndez-Lucas, Anna Esteve-Codina, Jose Luis Rosa, Francesc Ventura
Age-related and chemotherapy-induced bone loss depends on cellular senescence and the cell secretory phenotype. However, the factors secreted in the senescent microenvironment that contribute to bone loss remain elusive. Here, we report a central role for the inflammatory alternative complement system in skeletal bone loss. Through transcriptomic analysis of bone samples, we identified complement factor D, a rate-limiting factor of the alternative pathway of complement, which is among the most responsive factors to chemotherapy or oestrogen deficiency...
May 3, 2023: Molecular Therapy
https://read.qxmd.com/read/37113055/decoding-the-regulatory-roles-of-non-coding-rnas-in-cellular-metabolism-and-disease
#20
REVIEW
Yuru Zong, Xuliang Wang, Bing Cui, Xiaowei Xiong, Andrew Wu, Chunru Lin, Yaohua Zhang
Non-coding RNAs, including long non-coding RNAs (lncRNAs), microRNAs (miRNAs), and circular RNAs (circRNAs), are being studied extensively in a variety of fields. Their roles in metabolism have received increasing attention in recent years but are not yet clear. The regulation of glucose, fatty acid, and amino acid metabolism is an imperative physiological process that occurs in living organisms and takes part in cancer and cardiovascular diseases. Here, we summarize the important roles played by non-coding RNAs in glucose metabolism, fatty acid metabolism, and amino acid metabolism, as well as the mechanisms involved...
April 27, 2023: Molecular Therapy
journal
journal
34730
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.